Rainbow Children's Medicare Q1 FY27 profit rises 13%

Results snapshot and what changed

Rainbow Children's Medicare reported a year-on-year increase in profitability for Q1 FY27, alongside strong growth in revenue and operating profit. Consolidated net profit for the quarter was stated at INR 606 million, up from INR 534 million in the corresponding quarter last year. Revenue from operations rose to INR 4,699.9 million from INR 3,529.3 million, indicating sharp top-line growth. EBITDA increased to INR 1,346.5 million from INR 1,036.2 million. Even with higher EBITDA, the EBITDA margin softened to 28.7% from 29.4% a year earlier. The mix of faster revenue growth and slower profit growth was highlighted as a sign that costs below EBITDA, such as depreciation, finance costs, or taxes, may have increased.

Verification note on Q1 numbers

The source text flags the latest Q1 FY27 net profit figure as a claimed number that is “not independently verified.” In contrast, the Q1 FY26 baseline profit of INR 534 million is presented as verified in the same context. Because of this, the Q1 FY27 comparisons should be read as provisional until audited or independently confirmed numbers are available. The article also lists a scheduled board meeting on July 30, 2026 to consider and approve audited financial results for the quarter ended June 30, 2026. That meeting is the next formal checkpoint for investors tracking the reliability of the headline figures. Until then, the direction of change is clear in the source, but the precision of the latest quarter’s net profit should be treated cautiously.

Q1 FY27 versus Q1 FY26: the key operating picture

The most notable change in the quarter was the gap between revenue growth and margin movement. Revenue from operations increased 33.2% year-on-year to INR 4,699.9 million, while net profit rose 13.2% to INR 605.7 million (also stated elsewhere as INR 606 million). EBITDA grew 29.9% to INR 1,346.5 million, but the EBITDA margin moderated by 70 basis points to 28.7%. The source attributes strong revenue to higher patient volumes, improved occupancy, and network expansion. It also notes that a slower pace of net profit growth versus revenue can happen even when the underlying operating business remains strong. Overall, the quarter showed broad-based growth across revenue, EBITDA, and profit, with a small margin dip.

Sequential comparison: Q1 FY27 versus Q4 FY26

The same text compares Q1 FY27 to Q4 FY26 and notes a sequential decline in profit. Q4 FY26 consolidated profit after tax (PAT) is stated at INR 770.4 million (₹77.04 crore), compared with the claimed Q1 FY27 PAT of about INR 606 million. Q4 FY26 consolidated revenue is shown at INR 4,599.0 million (₹459.90 crore). The source describes the sequential softness as consistent with “pre-monsoon seasonal softness” typical in pediatric healthcare. It also mentions that Q4 FY26 EBITDA margin was approximately 31.1%, implying a sequential compression into Q1 FY27.

Acquisitions and consolidation impact on revenue base

The article points to consolidation benefits from acquisitions as a factor supporting Q1 revenue. It states that Q1 revenue is expected to benefit from the full-year consolidation of the Prashanthi and Pratiksha hospital acquisitions. This is described as providing a baseline uplift against the year-ago Q1 revenue of INR 3,529.3 million. While the source does not quantify the acquisition contribution, it frames the consolidation effect as one reason Q1 revenue growth appears strong. This context matters because it links growth not only to volumes and occupancy but also to changes in the revenue base.

Stock and valuation snapshot from the source

Market data in the text shows Rainbow Children's Medicare (NSE: RAINBOW, BSE: 543524) trading at ₹1,431.50, down ₹10.60 or 0.74% at 12:54 PM on BSE. The day’s range was ₹1,424.20 to ₹1,462.45, while the 52-week range was ₹1,008.75 to ₹1,644.10. A market capitalisation figure of ₹14,538.19 crore is listed in one place, while another line cites a market cap of ₹12,718 crore along with a P/E of 49.4. The snapshot also lists P/E at 58.15, P/B at 8.61, and EPS (TTM) at ₹24.62. These differing valuation and market-cap numbers suggest the data is pulled from multiple market widgets or time stamps within the source.

Key numbers table (INR million)

All rupee figures below are normalised to INR million (1 crore = 10 million), using the values stated in the source.

* Q1 FY27 profit is described as “claimed” and “not independently verified” in the source.
** Q1 FY26 profit appears as INR 534 million in the alert context and INR 538.1 million in the Q1FY26 highlights section.

What the quarter implies for investors

The quarter shows a pattern of rapid revenue expansion with a modest moderation in operating margin. Because net profit growth lagged revenue growth, readers should focus on cost lines below EBITDA when the audited release is available, as suggested by the source’s own explanation. The sequential drop from Q4 FY26 profit to Q1 FY27 profit is also a point the market may track, especially with the seasonal explanation provided. With acquisition consolidation referenced as a driver of the revenue base, investors may also watch whether margins stabilise as integration matures. The stock was lower on the day in the provided snapshot, but the text does not attribute the move to any single factor. The next concrete event in the timeline is the board meeting dated July 30, 2026 for audited results.

Conclusion

Rainbow Children's Medicare reported strong Q1 FY27 revenue growth and higher EBITDA, while the EBITDA margin eased and net profit rose at a slower pace. The latest Q1 net profit figure is flagged as not independently verified in the source, making the upcoming audited-result approval meeting a key near-term milestone.